Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Liu, Bicheng
NCT05136456: Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy	Active, not recruiting	2	61	RoW	SHR1459 Low Dose, SHR1459 High Dose, Placebo	Reistone Biopharma Company Limited	Primary Membranous Nephropathy	08/23	03/24
NCT05810961: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)	Terminated	2	8	RoW	efgartigimod IV, placebo	argenx, Zai Lab Pty. Ltd.	Membranous Nephropathy	08/24	08/24
NCT05810948: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Lupus Nephritis (ZL-1103-013)	Recruiting	2	60	RoW	efgartigimod IV, Placebo	argenx, Zai Lab (Shanghai) Co., Ltd.	Lupus Nephritis	07/25	09/25
NCT05515289: Study of SHR6390 in Renal Insufficiency and Healthy Subjects	Recruiting	1	30	RoW	SHR6390, dalpiciclib	Jiangsu HengRui Medicine Co., Ltd.	Breast Cancer	08/23	09/23
NCT06117852: Chronic Kidney Disease Registry Platform Study	Recruiting	N/A	5000	RoW		AstraZeneca	Chronic Kidney Diseases	12/26	12/26